Gruber, C.E.M.; Tucci, F.G.; Rueca, M.; Mazzotta, V.; Gramigna, G.; Vergori, A.; Fabeni, L.; Berno, G.; Giombini, E.; Butera, O.;
et al. Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients. Biomolecules 2023, 13, 1538.
https://doi.org/10.3390/biom13101538
AMA Style
Gruber CEM, Tucci FG, Rueca M, Mazzotta V, Gramigna G, Vergori A, Fabeni L, Berno G, Giombini E, Butera O,
et al. Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients. Biomolecules. 2023; 13(10):1538.
https://doi.org/10.3390/biom13101538
Chicago/Turabian Style
Gruber, Cesare Ernesto Maria, Fabio Giovanni Tucci, Martina Rueca, Valentina Mazzotta, Giulia Gramigna, Alessandra Vergori, Lavinia Fabeni, Giulia Berno, Emanuela Giombini, Ornella Butera,
and et al. 2023. "Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients" Biomolecules 13, no. 10: 1538.
https://doi.org/10.3390/biom13101538
APA Style
Gruber, C. E. M., Tucci, F. G., Rueca, M., Mazzotta, V., Gramigna, G., Vergori, A., Fabeni, L., Berno, G., Giombini, E., Butera, O., Focosi, D., Prandi, I. G., Chillemi, G., Nicastri, E., Vaia, F., Girardi, E., Antinori, A., & Maggi, F.
(2023). Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients. Biomolecules, 13(10), 1538.
https://doi.org/10.3390/biom13101538
